Summary: The Centers for Medicare & Medicaid Services modified its Vagus Nerve Stimulation coverage policy, with an effective date of May 15, 2026. Here's what billing teams need to do.
CMS vagus nerve stimulation coverage policy changes affect neurology, neurosurgery, and epilepsy practices billing for implantable VNS devices and related services. The policy does not list a specific policy code in the source document—it's tracked as a standalone modification in the CMS coverage framework. This policy update is effective May 15, 2026, and your billing team needs to review documentation requirements and medical necessity criteria before that date.
The underlying policy document did not publish specific CPT or HCPCS codes in the version captured at the time of this update. See the Affected Codes section for what that means for your charge capture process.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | CMS (Centers for Medicare & Medicaid Services) |
| Policy | Vagus Nerve Stimulation (VNS) |
| Policy Code | N/A |
| Change Type | Modified |
| Effective Date | May 15, 2026 |
| Impact Level | High |
| Specialties Affected | Neurology, Neurosurgery, Epilepsy, Cardiac Electrophysiology (for cardiac VNS indications) |
| Key Action | Audit VNS documentation packages for medical necessity compliance before May 15, 2026 |
CMS Vagus Nerve Stimulation Coverage Criteria and Medical Necessity Requirements 2026
Vagus nerve stimulation is not a simple claim. It carries one of the more scrutinized prior authorization and documentation profiles in Medicare neurology billing—and any modification to the CMS coverage policy raises the bar on what you need to support a paid claim.
The published policy source did not include the full criteria text in the version captured for this update. That means the specific changes to medical necessity language, indication thresholds, or documentation requirements are not available in this summary. What that tells you: pull the full policy directly from the CMS source before May 15, 2026, and do not assume prior criteria still apply.
What we do know from CMS's longstanding coverage framework for VNS: Medicare coverage has historically been tied to specific, narrow indications. Treatment-resistant epilepsy has been the primary covered indication under Medicare. Coverage for depression and other off-label uses has been far more restricted—and in many cases, considered non-covered or experimental. If this modification changed the indications list in either direction, your charge capture and ICD-10 coding will be directly affected.
The real risk here is billing for an expanded indication that CMS hasn't explicitly covered, or failing to document a newly required criterion that the updated policy now demands. Either path leads to claim denial. Document the clinical indication, the treatment history, and the prescribing physician's rationale before submitting.
Prior authorization requirements for VNS implantation have been a consistent feature of payer policy across the board—not just CMS. If you are billing for initial implantation, confirm prior auth status under the updated policy before scheduling. Retroactive prior auth is rarely granted for surgical implants, and the financial exposure is significant.
Reimbursement for VNS procedures involves multiple claim lines—the device, the implantation procedure, the programming sessions, and follow-up interrogations. Each component has its own documentation requirements. A policy modification at the coverage level can trigger changes to any or all of those components.
CMS Vagus Nerve Stimulation Exclusions and Non-Covered Indications
This section addresses what CMS has historically excluded from VNS coverage—and what billing teams should flag as high-risk until the full updated policy text is reviewed.
Depression treatment via VNS has been a contentious coverage issue for years. CMS issued a National Coverage Determination on VNS for treatment-resistant depression that effectively limited coverage to approved clinical trials. If the May 2026 modification changed that status—in either direction—your billing team needs to know immediately. Billing a depression indication under VNS outside of covered trial parameters is a direct path to claim denial and potential compliance exposure.
Cardiac applications of vagus nerve stimulation—including VNS for heart failure—are still largely investigational under Medicare. Cardiology practices exploring these devices should treat them as non-covered absent a specific, documented coverage determination.
Pain management indications, headache treatment, and inflammatory conditions are not covered under traditional CMS VNS policy. If any of these were modified in the May 2026 update, the policy source document will specify. Until you confirm the updated text, do not bill these indications expecting Medicare reimbursement.
If you're uncertain how the changes apply to your patient mix, talk to your compliance officer before May 15, 2026. VNS billing errors in Medicare can trigger recoupment and, in the worst cases, False Claims Act exposure. This is not a policy to interpret loosely.
Coverage Indications at a Glance
The policy source did not publish specific indication-level criteria in the version captured for this update. The table below reflects CMS's known historical coverage positions on VNS indications. Verify each row against the current policy text before May 15, 2026—this is not a substitute for the full policy.
| Indication | Historical Status | Notes |
|---|---|---|
| Treatment-resistant epilepsy (adjunctive therapy, adults) | Covered | Specific seizure frequency and prior treatment failure criteria typically required |
| Treatment-resistant epilepsy (adjunctive therapy, pediatric) | Covered with restrictions | Age and prior AED failure criteria apply; confirm updated thresholds |
| Treatment-resistant depression (non-trial) | Not Covered / Restricted | Historically limited to CMS-approved clinical trials; verify updated status |
| Heart failure / cardiac applications | Experimental / Not Covered | No broad Medicare coverage; trial-only or non-covered |
| Headache / migraine | Not Covered | Not supported under Medicare VNS coverage policy |
| Inflammatory conditions | Not Covered | Outside CMS covered indications |
| Alzheimer's disease | Experimental | No current Medicare coverage determination supporting this indication |
CMS Vagus Nerve Stimulation Billing Guidelines and Action Items 2026
The policy modification is effective May 15, 2026. These steps are time-sensitive.
| # | Action Item |
|---|---|
| 1 | Pull the full updated policy text now. The source document is available at the CMS policy record. Do not rely on this summary or prior policy versions after May 15, 2026. The specific criteria changes are in that document, and your team needs to read them. |
| 2 | Audit your active VNS patients for documentation compliance. For every patient currently receiving VNS therapy—or scheduled for implantation—confirm that the clinical record supports the indication under the updated criteria. If the modification tightened medical necessity thresholds, existing documentation may be insufficient for continued service claims. |
| 3 | Confirm prior authorization status for pending implantations. If you have VNS implantation procedures scheduled after May 15, 2026, verify that any prior auth obtained under old criteria is still valid. Some payers require re-authorization when the underlying coverage policy changes. CMS itself doesn't use prior auth in the traditional sense, but Medicare Advantage plans do—and those plans often follow CMS NCD changes with their own updates. Check each MA plan separately. |
| 4 | Update your charge capture workflows for any indication changes. If the policy modification expanded or narrowed covered indications, your coding team needs to know which ICD-10 diagnosis codes pair with covered vs. non-covered indications. Billing the wrong diagnosis code for VNS is one of the most common reasons these claims get flagged in post-payment audits. |
| 5 | Review your VNS programming and interrogation billing cadence. Ongoing VNS management generates recurring claims—device programming sessions, parameter adjustments, and routine interrogations. Coverage policy changes at the NCD level can affect whether ongoing management services are considered medically necessary beyond a certain point in treatment. If the policy now requires documented response or failure criteria to continue coverage, your follow-up visit documentation needs to reflect that. |
| 6 | Brief your neurology and neurosurgery coders before the effective date. This is not a policy change they should learn about from a returned claim. Schedule a 30-minute review before May 15, 2026, covering the updated indications, documentation requirements, and any diagnosis coding changes that follow from the modification. |
| 7 | Loop in your MAC if coverage applicability is unclear. Medicare Administrative Contractors have jurisdiction over coverage questions at the regional level. If the CMS modification left any gray areas—particularly around pediatric indications or newer device generations—your MAC's provider outreach line is the right call. Get their answer in writing. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Vagus Nerve Stimulation Under CMS Policy
The policy source document did not publish specific CPT, HCPCS Level II, or ICD-10-CM codes in the version captured for this update. PayerPolicy will update this section when the full code list becomes available from the source document.
Do not take the absence of a code list as confirmation that your existing codes are unchanged. The modification may have added or removed codes from covered status, and you need to verify against the full policy text.
Common Codes Associated with VNS Billing (Based on General Billing Knowledge—Verify Against Updated Policy)
The policy does not list specific codes. The following are commonly associated with VNS procedures in general billing practice. Confirm each against the actual May 2026 policy text before use. Do not treat this list as policy-verified.
VNS billing typically involves codes for device implantation, programming, revision, and removal. It also involves E/M codes for follow-up management and, depending on the setting, facility fees. Your vagus nerve stimulation billing team should map each service type to the applicable code and verify coverage status under the updated CMS policy before May 15, 2026.
If you have access to PayerPolicy's full policy record, the code tables will be populated as soon as the source document publishes the complete code list.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.